Click Here for 5% Off Your First Aladdin Purchase!

SBP-3264 , CAS No.S613473, Inhibitor of serine/threonine kinase 3;Inhibitor of serine/threonine kinase 4

  • Moligand™
Item Number
S613473
Grouped product items
SKUSizeAvailabilityPrice Qty
S613473-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
S613473-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,413.90

Basic Description

Synonymscompound 20;SBP 3264;SBP3264
Specifications & PurityMoligand™
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of serine/threonine kinase 3;Inhibitor of serine/threonine kinase 4

Associated Targets

RIOK3 Tchem Serine/threonine-protein kinase RIO3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

STK3 Tchem Serine/threonine-protein kinase 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

STK11 Tchem Serine/threonine-protein kinase STK11 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

STK4 Tchem Serine/threonine-protein kinase 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

LRRK2 Tchem Leucine-rich repeat serine/threonine-protein kinase 2 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BMP2K Tchem BMP-2-inducible protein kinase 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

PRKCQ Tchem Protein kinase C theta type 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

INCHI InChI=1S/C19H20ClN5O/c1-12(26)24-15-5-7-25(8-6-15)19-17-16(10-21-18(17)22-11-23-19)13-3-2-4-14(20)9-13/h2-4,9-11,15H,5-8H2,1H3,(H,24,26)(H,21,22,23)
InChi Key AYRVYPOFYQSRNH-UHFFFAOYSA-N
Canonical SMILES Clc1cccc(c2c[nH]c3ncnc(N4CCC(NC(=O)C)CC4)c23)c1
Isomeric SMILES CC(=O)NC1CCN(CC1)C2=NC=NC3=C2C(=CN3)C4=CC(=CC=C4)Cl
PubChem CID 162366980

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

References

1. Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A et al..  (2014)  Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers..  Nat Med,  20  (6): (599-606).  [PMID:24813251]
2. Wermke M, Camgoz A, Paszkowski-Rogacz M, Thieme S, von Bonin M, Dahl A, Platzbecker U, Theis M, Ehninger G, Brenner S et al..  (2015)  RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug..  Blood,  125  (24): (3760-8).  [PMID:25931586]
3. Camgoz A, Paszkowski-Rogacz M, Satpathy S, Wermke M, Hamann MV, von Bonin M, Choudhary C, Knapp S, Buchholz F.  (2018)  STK3 is a therapeutic target for a subset of acute myeloid leukemias..  Oncotarget,  (39): (25458-25473).  [PMID:29876001]
4. Bata N, Chaikuad A, Bakas NA, Limpert AS, Lambert LJ, Sheffler DJ, Berger LM, Liu G, Yuan C, Wang L et al..  (2021)  Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia..  J Med Chem,  129  (3): (589-97).  [PMID:34807584]

Solution Calculators